Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
NCT04879121 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Larotrectinib in Locally Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2021 and a primary completion date of 11 Nov 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04879121 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | M.D. Anderson Cancer Center |
| Enrollment | 13 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Locally Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm |
| Drugs | Larotrectinib |
| Start | 30 Apr 2021 |
| Primary completion | 11 Nov 2027 |
| Study completion | 11 Nov 2027 |
| Last update posted | 7 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- M D Anderson Cancer Center
Houston
David S. HongRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04879121
Each answer restates registry values shown on this page.
What is NCT04879121?
NCT04879121 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Larotrectinib in Locally Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm.
Is NCT04879121 recruiting?
As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT04879121?
The registry names David S Hong (principal investigator, M.D. Anderson Cancer Center) as the overall official.
Where does NCT04879121 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04879121 study?
The registered drug and biological interventions are Larotrectinib.
When is NCT04879121 expected to complete?
The registry lists a primary completion date of 11 Nov 2027 and a study completion date of 11 Nov 2027. The sponsor last updated the record on 7 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.